Cannabigerol (CBG) Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The Cannabigerol (CBG) market is estimated to be valued at USD 210 million in 2025 and is expected to reach USD 720 million by 2032, growing at a compound annual growth rate (CAGR) of 17.9% from 2025 to 2032. This impressive growth reflects increasing consumer awareness and expanding applications of CBG in various sectors, including pharmaceuticals, cosmetics, and wellness products, driving substantial investment and innovation within the industry.

Current market trends indicate a significant shift toward natural and plant-based remedies, with CBG gaining traction due to its therapeutic benefits such as anti-inflammatory, neuroprotective, and antibacterial properties. Additionally, regulatory advancements and increased research are facilitating product development and market penetration. The surge in demand for non-psychoactive cannabinoids is fostering new opportunities in personal care and healthcare segments, positioning CBG as a prominent growth driver in the evolving cannabinoid market landscape.

Segmental Analysis:

By Product Type: Dominance of Pure CBG Isolate Driven by Purity and Versatility

In terms of By Product Type, Pure CBG Isolate contributes the highest share of the Cannabigerol (CBG) market owing to its unmatched purity and versatility. Pure CBG Isolate is preferred by manufacturers and consumers alike because it offers a concentrated form of CBG with minimal impurities or other cannabinoids, which makes it highly suitable for precise formulation and targeted therapeutic applications. Its crystalline powder form allows for easy incorporation into various products, ranging from tinctures to edibles, without altering the taste or texture significantly. Moreover, the isolate enables product developers to deliver consistent dosages, a critical factor in pharmaceutical and wellness products where efficacy and safety are paramount. The increasing demand from end-users seeking cannabinoid products free from THC and other psychoactive elements further propels the isolate segment. Regulatory landscapes across multiple regions favor isolates due to their defined composition, streamlining compliance and quality assurance processes. Additionally, advances in extraction and purification technologies have reduced production costs and improved yield, making Pure CBG Isolate more accessible and affordable. The isolate's growing reputation for its potential anti-inflammatory, neuroprotective, and anti-bacterial properties stimulates research and innovation, which in turn fuels expanded applications and market uptake.

By Application: Pharmaceuticals Lead Through Therapeutic Potential and Research Backing

By Application, Pharmaceuticals contribute the largest share in the Cannabigerol (CBG) market, mainly because of CBG's promising therapeutic properties and increasing integration into medical treatments. CBG has shown potential in preclinical studies for addressing conditions such as glaucoma, inflammatory bowel disease, neurodegenerative disorders, and cancer, which encourages pharmaceutical companies to invest heavily in developing novel drugs and formulations containing CBG. The pharmaceutical segment benefits from stringent testing and clinical trials that validate the efficacy and safety of CBG-based medicines, creating trust among healthcare providers and patients. Moreover, rising prevalence of chronic diseases and unmet medical needs worldwide drive the search for alternative or adjunctive therapies, placing CBG in the spotlight as a viable candidate. Regulatory advancements enabling cannabinoid-based drug approvals further support this trend. Many pharmaceutical players focus on pure CBG formulations or combinations with other cannabinoids to maximize therapeutic outcomes and minimize side effects. The ability to produce precise, GMP-compliant pharmaceutical-grade CBG products aligns well with healthcare standards and expands CBG's use in prescription medications and over-the-counter remedies. Patient preference for natural and plant-derived medications also stimulates pharmaceutical interest, especially as research elucidates CBG's mechanisms of action and benefits.

By Source: Hemp-derived CBG Dominates Due to Legal Accessibility and Sustainability

In terms of By Source, Hemp-derived CBG holds the highest market share largely because of its favorable legal status and sustainability advantages. Hemp cultivation is widely legalized and regulated in many regions around the world, providing producers with a stable and scalable supply chain for extracting CBG. Unlike cannabis-derived CBG, which is often subject to stricter regulations due to psychoactive concerns, hemp-derived CBG contains negligible THC levels, making it easier to comply with legal frameworks. This accessibility lowers barriers for manufacturers and incentivizes investments in hemp farming and processing infrastructure. Additionally, hemp plants offer environmental benefits such as low water requirements and carbon sequestration, appealing to sustainability-conscious consumers and businesses. The hemp-derived segment also benefits from advancements in selective breeding techniques aimed at enhancing CBG content, which optimizes yield and cost-efficiency. Further, hemp's versatility allows simultaneous extraction of multiple cannabinoids, terpenes, and flavonoids, enabling producers to create broad-spectrum or full-spectrum products that cater to diverse consumer preferences. The continuously expanding acceptance of hemp-derived products in nutraceuticals, cosmetics, and wellness sectors reinforces demand for this source type, solidifying its leadership within the broader CBG market landscape.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the Cannabigerol (CBG) market is strongly influenced by a mature and well-established cannabis industry ecosystem and progressive government policies, particularly in the United States and Canada. The regulatory frameworks in many U.S. states and Canadian federal law permit hemp-derived CBG production, enabling manufacturers to invest heavily in research and product development. The region benefits from advanced agricultural technology, significant venture capital investments, and a broad consumer base familiar with cannabinoid products. Key industry players such as EcoGen Labs, Folium Biosciences, and CV Sciences have contributed extensively by innovating extraction technologies and expanding CBG-based wellness products, thereby consolidating North America's leading position. Furthermore, well-developed supply chain infrastructures and export capabilities amplify the region's competitive advantage.

Fastest-Growing Region: Europe

Meanwhile, Europe exhibits the fastest growth in the CBG market, driven by evolving regulatory acceptance and increasing consumer awareness about cannabinoids' therapeutic benefits. Countries such as Germany, the Netherlands, and Switzerland are fostering favorable policies supporting hemp cultivation and the use of cannabinoids in nutraceuticals and pharmaceuticals. The European Union's harmonizing regulatory directives related to CBD and related compounds have opened new avenues for CBG commercialization, attracting significant investments from local and international firms. Companies like CannaCraft Europe, Endoca, and SusAdvantage are elevating the regional landscape by focusing on organic cultivation practices, product purity, and clinical research collaborations. Trade dynamics, including eased cross-border distribution within the EU, further accelerate growth and market penetration.

CBG Market Outlook for Key Countries

United States

The United States continues to lead the CBG market with its robust regulatory developments at state levels and a dynamic cannabis research environment. Major players such as Folium Biosciences and EcoGen Labs drive innovation through advanced extraction techniques and product diversification in wellness, cosmetics, and therapeutic sectors. The growing acceptance among medical users and wellness consumers fuels demand. Furthermore, extensive agricultural know-how and capital accessibility provide a strong foundation for scaling CBG production and distribution across various segments.

Canada

Canada's CBG market benefits from the fully legal cannabis framework, allowing seamless integration of CBG into the broader cannabinoid product portfolio. Companies like Canopy Growth Corporation and Aurora Cannabis support the market through large-scale cultivation and R&D in minor cannabinoids, including CBG. Canada's stable regulatory environment encourages collaboration between industry and research institutions, resulting in high-quality and consistent CBG products targeting medical and recreational consumers. The country's export-oriented approach also positions it as a significant supplier for global markets.

Germany

Germany represents a critical European hub for the CBG market due to its leadership in medicinal cannabis adoption and supportive regulatory stance. Producers such as Endoca and CannaTech are pivotal in harnessing locally grown hemp for CBG extraction, backed by rigorous quality standards. The nation's healthcare infrastructure provides a viable pathway for CBG-based therapeutics, while increasing public interest in alternative wellness supplements boosts retail availability. Germany's strategic location also facilitates broader distribution across the EU.

Netherlands

The Netherlands is notable for its progressive cannabis policies and rich history in cannabis research and innovation, making it a fertile ground for CBG development. Key companies like Bedrocan and SusAdvantage actively invest in clinical research and product standardization, which helps build consumer confidence. The Dutch market draws widespread international attention due to its export potential and strong cultivation expertise. The country's trade-friendly policies enhance accessibility of CBG products across European markets.

Australia

Australia's emerging CBG market is characterized by careful regulatory frameworks focused on medicinal cannabis and hemp-derived cannabinoids. Firms such as Little Green Pharma and CannPal Animal Therapeutics are prominently involved in advancing CBG applications, especially in pharmaceutical and veterinary sectors. Increasing government support for local cultivation and clinical trial initiatives underpins the cautious yet rapid market development. Australia's geographic position also makes it a key player in the Asia-Pacific region's expanding interest in cannabinoid products.

Market Report Scope

Market Segmentation

Product Type Insights (Revenue, USD, 2020 - 2032)

• Pure CBG Isolate
• CBG Oil
• CBG-infused Edibles
• Topical CBG Products
• Others

Application Insights (Revenue, USD, 2020 - 2032)

• Pharmaceuticals
• Nutraceuticals
• Cosmetics & Personal Care
• Animal Healthcare
• Others

Source Insights (Revenue, USD, 2020 - 2032)

• Hemp-derived CBG
• Cannabis-derived CBG
• Synthetic CBG
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Aurora Cannabis
• Cronos Group
• Endoca
• Elixinol Wellness
• GW Pharmaceuticals
• Village Farms International
• Herbalgram
• Canopy Growth Corporation
• HEXO Corp
• MediPharm Labs
• Integrity Botanicals
• Farmacy Bliss
• Spectrum Therapeutics
• Thought Labs
• TerraVida Holistics
• PhytoVista Laboratories